Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of PD-1 Inhibitor market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of PD-1 Inhibitormarket, defines the market attractiveness level of PD-1 Inhibitor market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of PD-1 Inhibitor industry, describes the types of PD-1 Inhibitor market, the applications of major players and the market size, and deeply analyzes the current situation of the global PD-1 Inhibitor market and the development prospects and opportunities of PD-1 Inhibitor industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global PD-1 Inhibitor market in Chapter 13.
By Player:
Pfizer
Genentech (Roche)
AstraZeneca
Onxeo
Sumitomo Dainippon Pharma
Taiwan Liposome Company
Merck
Tiziana Life Sciences
Novartis
By Type:
Pembrolizumab
Nivolumab
Atezolizumab
Durvalumab
Avelumab
Other
By End-User:
Melanoma
Non-small Cell Lung Cancer (NSCLC)
Urothelial Carcinoma
Classical Hodgkin Lymphoma
Renal Cell Carcinoma
Other
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 PD-1 Inhibitor Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 PD-1 Inhibitor Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 PD-1 Inhibitor Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 PD-1 Inhibitor Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise PD-1 Inhibitor Market Analysis and Outlook to 2022
-
7.1 Global PD-1 Inhibitor Consumption (2017-2022)
-
7.2 United States PD-1 Inhibitor Consumption (2017-2022)
-
7.3 Europe PD-1 Inhibitor Consumption (2017-2022)
-
7.4 China PD-1 Inhibitor Consumption (2017-2022)
-
7.5 Japan PD-1 Inhibitor Consumption (2017-2022)
-
7.6 India PD-1 Inhibitor Consumption (2017-2022)
-
7.7 South Korea PD-1 Inhibitor Consumption (2017-2022)
8 Region and Country-wise PD-1 Inhibitor Market Analysis and Outlook to 2028
-
8.1 Global PD-1 Inhibitor Consumption Forecast (2022-2028)
-
8.2 United States PD-1 Inhibitor Consumption Forecast (2022-2028)
-
8.3 Europe PD-1 Inhibitor Consumption Forecast (2022-2028)
-
8.4 China PD-1 Inhibitor Consumption Forecast (2022-2028)
-
8.5 Japan PD-1 Inhibitor Consumption Forecast (2022-2028)
-
8.6 India PD-1 Inhibitor Consumption Forecast (2022-2028)
-
8.7 South Korea PD-1 Inhibitor Consumption Forecast (2022-2028)
9 Global PD-1 Inhibitor Market Outlook by Types and Applications to 2022
-
9.1 Global PD-1 Inhibitor Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Pembrolizumab Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Nivolumab Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Atezolizumab Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Durvalumab Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Avelumab Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Other Consumption and Growth Rate (2017-2022)
-
9.2 Global PD-1 Inhibitor Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Melanoma Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Non-small Cell Lung Cancer (NSCLC) Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Urothelial Carcinoma Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Classical Hodgkin Lymphoma Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Renal Cell Carcinoma Consumption and Growth Rate (2017-2022)
-
9.2.6 Global Other Consumption and Growth Rate (2017-2022)
10 Global PD-1 Inhibitor Market Outlook by Types and Applications to 2028
-
10.1 Global PD-1 Inhibitor Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Pembrolizumab Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Nivolumab Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Atezolizumab Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
10.1.5 Global Avelumab Consumption Forecast and Growth Rate (2022-2028)
-
10.1.6 Global Other Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global PD-1 Inhibitor Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Melanoma Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Non-small Cell Lung Cancer (NSCLC) Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Classical Hodgkin Lymphoma Consumption Forecast and Growth Rate (2022-2028)
-
10.2.5 Global Renal Cell Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
10.2.6 Global Other Consumption Forecast and Growth Rate (2022-2028)
11 Global PD-1 Inhibitor Import and Export Analysis (Top 5 Countries)
-
11.1 Global PD-1 Inhibitor Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global PD-1 Inhibitor Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 PD-1 Inhibitor Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global PD-1 Inhibitor Market Competitive Analysis
-
14.1 Pfizer
-
14.1.1 Pfizer Company Details
-
14.1.2 Pfizer PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Pfizer PD-1 Inhibitor Product and Service
-
14.2 Genentech (Roche)
-
14.2.1 Genentech (Roche) Company Details
-
14.2.2 Genentech (Roche) PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Genentech (Roche) PD-1 Inhibitor Product and Service
-
14.3 AstraZeneca
-
14.3.1 AstraZeneca Company Details
-
14.3.2 AstraZeneca PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 AstraZeneca PD-1 Inhibitor Product and Service
-
14.4 Onxeo
-
14.4.1 Onxeo Company Details
-
14.4.2 Onxeo PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Onxeo PD-1 Inhibitor Product and Service
-
14.5 Sumitomo Dainippon Pharma
-
14.5.1 Sumitomo Dainippon Pharma Company Details
-
14.5.2 Sumitomo Dainippon Pharma PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Sumitomo Dainippon Pharma PD-1 Inhibitor Product and Service
-
14.6 Taiwan Liposome Company
-
14.6.1 Taiwan Liposome Company Company Details
-
14.6.2 Taiwan Liposome Company PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Taiwan Liposome Company PD-1 Inhibitor Product and Service
-
14.7 Merck
-
14.7.1 Merck Company Details
-
14.7.2 Merck PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Merck PD-1 Inhibitor Product and Service
-
14.8 Tiziana Life Sciences
-
14.8.1 Tiziana Life Sciences Company Details
-
14.8.2 Tiziana Life Sciences PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Tiziana Life Sciences PD-1 Inhibitor Product and Service
-
14.9 Novartis
-
14.9.1 Novartis Company Details
-
14.9.2 Novartis PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Novartis PD-1 Inhibitor Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of PD-1 Inhibitor
-
Figure PD-1 Inhibitor Picture
-
Table Global PD-1 Inhibitor Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global PD-1 Inhibitor Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global PD-1 Inhibitor Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global PD-1 Inhibitor Consumption by Country (2017-2022)
-
Figure United States PD-1 Inhibitor Consumption and Growth Rate (2017-2022)
-
Table Europe PD-1 Inhibitor Consumption and Growth Rate (2017-2022)
-
Figure China PD-1 Inhibitor Consumption and Growth Rate (2017-2022)
-
Figure Japan PD-1 Inhibitor Consumption and Growth Rate (2017-2022)
-
Figure India PD-1 Inhibitor Consumption and Growth Rate (2017-2022)
-
Figure South Korea PD-1 Inhibitor Consumption and Growth Rate (2017-2022)
-
Figure Global PD-1 Inhibitor Consumption Forecast by Country (2022-2028)
-
Figure United States PD-1 Inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe PD-1 Inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Figure China PD-1 Inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan PD-1 Inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Figure India PD-1 Inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea PD-1 Inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Pembrolizumab Consumption and Growth Rate (2017-2022)
-
Figure Global Nivolumab Consumption and Growth Rate (2017-2022)
-
Figure Global Atezolizumab Consumption and Growth Rate (2017-2022)
-
Figure Global Durvalumab Consumption and Growth Rate (2017-2022)
-
Figure Global Avelumab Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Melanoma Consumption and Growth Rate (2017-2022)
-
Figure Global Non-small Cell Lung Cancer (NSCLC) Consumption and Growth Rate (2017-2022)
-
Figure Global Urothelial Carcinoma Consumption and Growth Rate (2017-2022)
-
Figure Global Classical Hodgkin Lymphoma Consumption and Growth Rate (2017-2022)
-
Figure Global Renal Cell Carcinoma Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Pembrolizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Nivolumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Atezolizumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Durvalumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Avelumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Melanoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Non-small Cell Lung Cancer (NSCLC) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Classical Hodgkin Lymphoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Renal Cell Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Table Global PD-1 Inhibitor Import by Region (Top 5 Countries) (2017-2028)
-
Table Global PD-1 Inhibitor Export by Region (Top 5 Countries) (2017-2028)
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer PD-1 Inhibitor Product and Service
-
Table Genentech (Roche) (Foundation Year, Company Profile and etc.)
-
Table Genentech (Roche) PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genentech (Roche) PD-1 Inhibitor Product and Service
-
Table AstraZeneca (Foundation Year, Company Profile and etc.)
-
Table AstraZeneca PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca PD-1 Inhibitor Product and Service
-
Table Onxeo (Foundation Year, Company Profile and etc.)
-
Table Onxeo PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
Table Onxeo PD-1 Inhibitor Product and Service
-
Table Sumitomo Dainippon Pharma (Foundation Year, Company Profile and etc.)
-
Table Sumitomo Dainippon Pharma PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sumitomo Dainippon Pharma PD-1 Inhibitor Product and Service
-
Table Taiwan Liposome Company (Foundation Year, Company Profile and etc.)
-
Table Taiwan Liposome Company PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
Table Taiwan Liposome Company PD-1 Inhibitor Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck PD-1 Inhibitor Product and Service
-
Table Tiziana Life Sciences (Foundation Year, Company Profile and etc.)
-
Table Tiziana Life Sciences PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
Table Tiziana Life Sciences PD-1 Inhibitor Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis PD-1 Inhibitor Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis PD-1 Inhibitor Product and Service
-
